FDA Inspection 1287242 — Pierre Fabre Medicament
The FDA completed an inspection of Pierre Fabre Medicament on Jul 8, 2022 in Gaillac. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jul 8, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Gaillac (France)
Additional Details
Mutual Recognition Agreement (MRA)